3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
7
Stomach Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasm Metastasis
3
Neoplasms
2
Rectal Neoplasms
1
Rectal Diseases
1
Intestinal Neoplasms
1
Intestinal Diseases
1
HER2+ Metastatic Breast Cancer (MBC)
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Colonic Diseases
1
Brain Neoplasms
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
Interventions
neratinib
1
Lapatinib
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
HER2+ Metastatic Breast Cancer (MBC)
×
Capecitabine
×
Clear all
NCT01808573
2021-06-11
NALA
Puma Biotechnology, Inc.
Phase 3
Completed
621 enrolled
21 charts
1 FDA